Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Why do some people with severe obesity develop kidney disease?

NCT ID NCT07830030

NEW Knowledge-focused Sponsor: Clinique Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are following 480 adults with severe obesity in Guadeloupe and French Polynesia for five years. The study checks whether having metabolic syndrome, a cluster of conditions like high blood pressure and high blood sugar, raises the risk of chronic kidney disease, heart problems, diabetes, and death. The team also looks at gene variants tied to belly fat and kidney disease to see how they relate to these outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the study finds links between metabolic syndrome, gene variants, and kidney or heart complications, it could help doctors identify which people with severe obesity face the highest risk and guide earlier monitoring.
What could go wrong
This is an observational study, so it can show associations but cannot prove cause and effect. Five years of follow-up may miss slower changes, and findings in Caribbean and Polynesian populations may not apply to other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 480 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Individuals suffering from morbid obesity may be selected for the study at the outpatient or inpatient departments involved in the management of this metabolic disease. Patients will be enrolled at four sites: i) The Obesity-Nutrition Day Hospital at the Basse-Terre CMS in Guadeloupe; ii) The Medical Department at the NEM Clinic in Guadeloupe; iii) The SSR (Post-acute and Rehabilitation Care) Department at Ora Ora in French Polynesia; iv) The Medicine C Department at the Basse-Terre Hospital Center (CHBT) in Guadeloupe

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patient enrollment will be conducted consecutively. Individuals with a BMI ≥ 40 kg/m² or \> 35 kg/m² with at least one comorbidity (hypertension, diabetes, hypercholesterolemia, joint pain, obstructive sleep apnea syndrome, etc.) * With no history of bariatric surgery, or having undergone such a procedure more than 5 years ago * Aged 18 years or older * Informed of the study objectives and constraints and having provided written consent; residents of Guadeloupe or French Polynesia Exclusion Criteria: * Refusal to participate Individuals with acute renal failure; those undergoing dialysis Those who have undergone bariatric surgery within the last 5 years Pregnant women, women in labor, and breastfeeding mothers Persons deprived of liberty by a judicial or administrative decision; persons subject to psychiatric care Minors Adults subject to legal protection measures or unable to provide consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease (stage 3-4) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome metabolic syndrome X morbid obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease (stage 3-4) Morbid obesity

Contacts and locations

Locations

  • NEM

    Le Moule, Guadeloupe, 97160, Guadeloupe

More trials for these conditions

Other studies related to the condition(s) this trial covers.